Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors, advances in nuclear medicine in the field ...

Swiss drugmaker Novartis predicted that the Australian government would not defend its nuclear medicine world technology ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

Scientists from Tomsk Polytechnic University, in collaboration with their colleagues, supported by the federal Priority-2030 ...

Priya Jacob has contributed to nuclear medicine and radiation oncology by integrating AI-driven diagnostics, optimizing PET-CT and SPECT-CT, and enhancing treatment precision. Her work in Theranostics ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, ...

Results from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.

Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic ...

Phase 2 trial design will seek to maximise radiation doses to tumor and extend the duration of therapy, with first metastatic ...

This partnership also extends to the distribution of our Lutetium (177 Lu ... of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer in the following clinical ...